Anal intraepithelial neoplasia (AIN) is a precancerous condition of anal canal, which like its counterpart in the cervix, cervical intraepithelial neoplasia (CIN), can progress to invasive cancer. Like CIN, there is a spectrum of AIN, graded as AIN I, II, or III depending on the extent of nuclear abnormalities. AIN I has nuclear abnormalities confined to the lower one third of the epithelium. A common form of AIN 1 is condyloma acuminatum. Nuclear abnormalities in AIN 2 are confined to the lower two-thirds and in AIN 3 to the entire thickness of the epithelium.1,2 AIN is strongly associated with human papillomavirus (HPV) infection. Both nononcogenic (low risk) types of HPV such as HPV 6 and HPV 11 and oncogenic (high risk) types such as HPV 16 and HPV 18 are implicated in AIN 1, whereas AIN 3 and anal squamous cell cancer are associated with oncogenic HPV types.1 Beside HPV, other significant risk factors for anal cancer include smoking, anal fissure, anal fistula, and hemorrhoids (greater than 12 episodes).3 Most cases of AIN occur within the anal canal, particularly the anal transition zone, but AIN and anal cancer can also occur on the perianal skin.
The incidence of anal cancer has been increasing over the past 4 decades.4,5 Though the incidence of anal cancer is low in the general population,6,7 it is reported to be as high as 35 per 100,000 in men who have a history of receptive anal intercourse.8 Even higher risk for anal cancer has been observed in both men and women with HIV infection.9-11 Investigators estimate that the incidence of anal cancer among HIV-positive men who have sex with men (MSM) may be as high as 70-100 cases per 100,000 individuals.12 Like anal cancer, the incidence of AIN is also higher in HIV-positive men and women compared with the general population (relative risk of 60 and relative risk of 7.8, respectively).1,13,14 Most studies show that the introduction of highly active antiretroviral therapy (HAART) has not had an appreciable positive effect on prevalence or incidence of AIN in HIV-positive patients despite an increase in CD4 cell counts observed with therapy.2,15-19 Consistent with these findings, the incidence of anal cancer has continued to increase since the introduction of HAART.2,15-19 Taken together, these data indicate that AIN and anal cancer will continue to remain a serious clinical problem, particularly among HIV-positive men and women.
Topical 85% trichloroacetic acid (TCA) is one of the accepted cytotoxic therapies for condyloma and is recommended by Center for Disease Control as one of the first-line treatments for condyloma acuminatum.20 The University of California San Francisco (UCSF) Anal Neoplasia Clinic has been using TCA for the treatment of AIN for the past 9 years. However, little is known about its efficacy and long-term clearance rates when used to treat intraanal AIN of different grades of severity. TCA represents a potentially attractive treatment approach because it is inexpensive, is generally well tolerated by patients, has no systemic side effects, and is safe to use in pregnancy.6
The purpose of this study was to perform a retrospective chart review of patients seen in the UCSF Anal Neoplasia Clinic who received first-line 85% TCA therapy for AIN of different grades in a population mostly consisting of HIV-positive MSM.
Retrospective review of medical records was performed for all patients at the UCSF Anal Neoplasia Clinic whose first-line treatment for AIN was TCA between January 1, 2000, and December 31, 2004. The inclusion criteria were age older than 18 years; no treatment with TCA before January 1, 2000, lesions less than 1 cm2 in size at the base, and patients' ability to return for regular follow-up visits. HIV-positive and HIV-negative patients were studied. Both external and internal lesions were treated. Both flat and raised lesions were treated if they met the inclusion criteria.
Patients were generally referred to the clinic after anal cytology smears performed by outside community physicians were reported to be abnormal. At the first visit, a detailed history and physical exam was performed on every patient. HIV-positive patients were questioned about their most recent CD4+ counts, HIV viral loads, and their HIV history. A swab was inserted to collect cells for Thinprep anal cytology. After a digital rectal examination was performed, high resolution anoscopy (HRA) was performed as described previously using 3% acetic acid and colposcopic magnification.12 The number and extent of lesions was recorded, and a biopsy was performed of visible lesions. Anal cytology was used to determine the grade of AIN in patients in whom biopsy results were unsatisfactory or in whom biopsy could not be performed. When both an anal cytology and biopsy were available, the most severe grade of these 2 tests was used for analysis.
Most patients for whom TCA treatment was selected were seen within 1-2 months of the first visit to initiate their treatment. At the treatment visit, an anoscope was inserted and HRA was performed as described previously, and the lesions were treated with 85% TCA by dipping the wooden stick end of a cotton swab into a cup containing about 250 μL of TCA. The stick end was saturated with TCA and was inserted through the anoscope and directed to the lesion under colposcopic guidance. TCA was applied to the lesion repeatedly until the lesion turned dense white color. The patient was counseled to expect anal bleeding for up to 2 weeks with bowel movements and to avoid straining or anal intercourse during this time.
During this time, each TCA application was followed by another appointment 1-2 months later, when the clinician reevaluated the patient to determine whether more TCA was necessary. First-line treatment consisted of up to 4 applications of TCA at 1-2 month intervals. Clearance was defined as the absence of AIN confirmed by absence of visible disease on HRA after up to 4 TCA treatments. If AIN cleared within 4 TCA applications, first-line therapy was considered successful, and patients were then followed at 3, 6, and 12 months after the last evaluation at which they were found to be clear. If they still had AIN despite 4 treatments of TCA, they were considered to have failed the first-line treatment, that is, even if TCA was able to clear some lesions, it was not considered to be successful unless it cleared all AIN. Recurrence was defined as detection of AIN during the follow-up period after its resolution with the first-line therapy. Most patients who failed TCA therapy were then referred to receive infrared coagulation (IRC) or surgery. Patients who cleared anytime during the first set of 4 TCA applications, but whose AIN recurred during 3-month, 6-month, or 12-month follow-ups, were also referred for IRC or surgery. Amongst the patients with AIN 2/3, we also measured the rate of regression of their AIN 2/3 to low-grade AIN (AIN 1). Hence, we defined cure of AIN 2/3 as conversion to AIN 1 and its complete disappearance. In addition to per patient clearance, we measured clearance of AIN on a per lesion basis.
Statistical analysis was performed using SAS Version 9.1 (SAS Institute, Cary, NC). SAS Procedure FREQ was used to compute the exact confidence intervals (CIs) for the clearance and recurrence rates. SAS Procedure LOGISTIC was used to perform exact logistic regression.
Fifty-four male patients met the inclusion criteria. The demographics of the study population are shown in Table 1. On the first visit, we determined the grade of AIN using either biopsy or cytology in 47 of 54 patients. The remaining 7 patients did have biopsy or cytology at the first visit during the follow-up course and were found to have AIN. Overall, 35 of 54 patients (65%) were HIV positive and 19 (35%) were HIV negative. Sixty-three percent of all HIV-positive patients were on HAART. There were no statistically significant differences between the HIV-positive and HIV-negative patients with respect to age, race, and number of lesions or severity of lesions (Table 1).
We examined complete clearance of lesions and clearance of AIN 2/3 lesions to AIN 1 or less on a per patient and per lesion basis, and the results are shown in Table 2. Of 28 patients with histologically confirmed AIN 2/3 lesions, 9 (32%) resolved completely and 8 (29%) resolved to AIN 1. Of 19 patients with histologically confirmed AIN 1 lesions at the first visit, 6 (32%) resolved completely. Of 55 histologically confirmed AIN 2/3 lesions, 35 (64%) resolved completely and 4 (7%) resolved to AIN 1. Of 70 histologically confirmed AIN 1 lesions at the first visit, 51 (73%) resolved completely. The odds of clearance for AIN 2/3 compared with AIN-1 on a per lesion basis when adjusted for HIV status was 0.6 (95% CI: 0.3 to 1.3, P = 0.2). The odds of clearance of lesions in HIV-positive individuals compared with HIV-negative individuals on a per lesion basis was 0.55 (95% CI: −0.2 to 1.5, P = 0.2).
Of the HIV-positive patients, 34% achieved complete clearance with up to 4 treatments with TCA, compared with 47% of HIV-negative patients (OR: 0.6, 95% CI: 0.2 to 2.1, P = 0.5). Of the 21 patients who cleared AIN, 9 patients required only 2 TCA treatments to clear completely; 3 patients required 1 treatment; 4 patients required 3 treatments; and 5 patients cleared after 4 treatments. Patients who cleared required a mean of 2.5 treatments and median of 2 treatments.
Only 3 of 54 patients (5%) reported side effects with TCA, usually local discomfort and pain. One patient reported exacerbation of preexisting psoriasis, and none had serious side effects such as local ulceration, abscess, or bleeding.
Risk factors associated with clearance of lesions on a per patient basis after TCA therapy are shown in Table 3. In the analysis adjusted for HIV status, with all patients combined, men in the 41-48 years age group were more likely to achieve complete clearance with TCA (OR: 8.4, 95% CI: 1.1 to 94, P = 0.04). The OR for clearance was also higher among men younger than 41 years compared with greater than 49, but the result did not reach statistical significance.
Among HIV-positive patients with 1 lesion, 48% showed clearance compared with 18% of HIV-positive patients with 4 or more lesions. In univariate analysis on a per patient basis, HIV-positive subjects showed significantly greater likelihood of clearance in patients with ≤2 lesions (OR: 14.3, 95% CI: 1.5 to 661.7, P = 0.01) compared with those with 3-4 lesions. Additionally, although not statistically significant, HIV-positive patients showing clearance of the lesions were found to have higher CD4+ counts when compared with those not showing clearance. A nonsignificant trend toward greater clearance was observed in the combined patient population with less than or equal to 2 versus 3-4 lesions (OR: 3.5, 95% CI: 0.90 to 14.7, P = 0.08).
Recurrence was defined as detection of AIN during the follow-up period after its resolution with the first-line therapy and was observed within a mean period of 6 months in 15 of 21 patients (72%) who had shown clearance previously. Six of 9 HIV-negative patients (67%) and 9 of 12 HIV-positive patients (75%) showed recurrence. In univariate analysis, the recurrence rate in patients with AIN 2/3 was higher than that in patients with AIN 1 (OR: 5.1, 95% CI: 0.2-313.8, P = 0.6), but this was not statistically significant. A trend toward greater recurrence was also seen in younger patients compared with older age groups (OR: 3.2, 95% CI: 0.3 to 45.3, P = 0.5). Recurrence was seen in 10 of 16 patients with 2 or fewer lesion, whereas it was seen in 5 out of 6 patients with 3 or more lesions (OR: 0.6, 95% CI: 0.04 to 10, P = 1), but this was not statistically significant.
AIN is a known precursor of invasive cancer21 with an estimated progression rate of AIN to squamous cell cancer of about 11% over a period of 42 months of follow-up. Although AIN 1 has a low risk of progression to malignancy, it has been observed that around 62% of HIV-positive men and 36% of HIV-negative men with baseline AIN 1 progress to AIN 2-3 over a 2-year follow-up period.22 Thus, there are potential benefits to treating both AIN 1 and AIN 2-3.
Analogous to cervical cytology screening to identify and treat CIN lesions before they progress to cervical cancer, anal cytology screening programs have been proposed to identify and treat AIN before it progresses to anal cancer in high-risk groups.23,24 Anal cytology is 69% sensitive and 59% specific in detecting any grade of anal dysplasia in HIV-positive men, whereas its sensitivity and specificity in HIV-negative men is 47% and 92%, respectively, when Atypical Squamous Cells of Undetermined Significance (ASCUS) is included as an abnormal cytology.25 Goldie et al have concluded that anal cytological screening in HIV-negative homosexual and bisexual men every 2-3 years and in HIV-positive men yearly, followed by treatment of high-grade AIN, would be optimal and cost effective to prevent anal cancer.23,24
One of the barriers toward implementation of such a screening program has been the paucity of data on the treatment of AIN. Few studies have been published on the success of different treatment modalities to clear AIN lesions. Although it has not yet been proven in clinical trials, based on the analogy with the cervix, it is assumed that clearance of AIN will prevent progression of that lesion to anal cancer.
TCA is one of the accepted cytotoxic therapies for AIN, primarily AIN 1 in the form of condyloma acuminatum especially for smaller lesions.1,2 Few studies have compared TCA with other modalities. One study comprising 130 presumably HIV-negative men with penile condyloma randomly allocated to treatment with either TCA or cryotherapy concluded that there was no significant difference in the cure rates and subsequent recurrence rates between the 2 modalities. The clearance rates after 5 treatments of TCA and cryotherapy were 81% and 88%, respectively, and the recurrence rates over a period of 2 months with TCA and cryotherapy were 36% and 39%, respectively.25
In our study, the clearance rates of AIN on a per patient basis with TCA in HIV-negative patients and HIV-positive patients were 47% and 34%, respectively. On a per lesion basis (AIN 1, AIN 2/3, and lesions of unknown grade), the average rate of clearance of all lesions was somewhat higher at 64%. Defined as complete clearance and conversion to AIN 1, the overall response rate of AIN 2/3 was also quite high at 71%. Although doing per patient analysis, we did not biopsy every lesion after treatment but used very rigorous definitions for treatment response, that is, complete absence of all lesions (and not merely reduction to a lower grade) after visualization with HRA. Our per lesion clearance results are comparable to the clearance rates in the above mentioned earlier studies that determine the efficacy of TCA in treating genital warts.25 However, the studies are not strictly comparable because in the earlier study TCA was used to treat genital warts which are mainly caused by nononcogenic types of HPV (6 and 11), whereas AIN 2/3 is caused by oncogenic HPV types (16, 18, 31, and others).
We found TCA to be a safe outpatient treatment option for AIN as only 5% of treated patients complained of mild side effects, that is, local discomfort and flare up of preexisting psoriasis. Health care providers also find it safe and easy to use. Though there is no consensus regarding treatment of flat AIN 1, our earlier published data show high progression to AIN 2-3 over 2 years. Hence, we treated AIN 1 when feasible.22 TCA can be applied to more than 1 lesion at a time, allowing treatment of multiple lesions in a single visit. TCA is also relatively inexpensive. Our results show that TCA may be a useful first-line therapy in the patients younger than 50 years of age with 1-2 lesions; clearance was substantially lower among those with more than 2 lesions. Although patients presenting with this limited degree of disease would be relatively rare in a referral population such as ours, we expect that these patients would be more common in a population that was being actively and routinely screened for AIN.
Neither the grade nor the HIV status was significantly associated with response rates, although this may reflect the small sample size of the study. TCA is probably less effective in large bulky condylomas, which, despite being classified as AIN 1, are hyperkeratotic and would respond poorly due to poor penetration at the base of the lesion.
Among those who did clear, the per patient recurrence rate was quite high, with our data showing a trend to recurrence that was higher in patients with AIN 2-3. The recurrence rate was likely overestimated because any new lesion that was diagnosed after initial clearance was counted as recurrent, and many of these may have been new lesions unrelated to the treated lesions. Whether or not these lesions are truly recurrent, these data do point to the need to continue to monitor patients even after successful therapy.
To our knowledge, this is the first study that demonstrates the efficacy of TCA in long-term clearance of AIN. A number of other treatment options are available for AIN for whom TCA is not suitable or who fail TCA, including immunomodulation, locally ablative procedures and surgery.26 Earlier studies have shown that surgery for AIN is associated with a poor outcome in HIV-positive patients because of high persistence and recurrence rates after single procedure and significant postoperative morbidity.27-29
In another study, 23 of 29 HIV-positive patients showed persistent/recurrent disease (P < 0.003) after surgery.30 This result should be interpreted with caution because surgery was reserved for patients who had the largest lesions or who had failed other treatment modalities. However, a more recent retrospective study from the same group showed better results.31 After an average follow-up for 44 months, 78% of patients treated surgically remained free of AIN 2-3 and the rate of progression to squamous cell carcinoma (SCC) was only 1.2%. Treatment complications included anal stenosis, bleeding requiring reoperation, anal fissure, myocardial infarction, and cellulitis.
IRC is also an effective treatment for AIN in both HIV-positive and HIV-negative men.32-34 It has been reported that the cure rate of AIN 2-3 with IRC with the average number of lesions being 1.6 in HIV-positive MSM was 72%.33 After IRC, 65% of treated HIV-positive individuals developed new AIN 2-3 in a mean of 217 days and 28% persisted. After second and third treatments, the new/persistent lesions dropped to 58% and 40%, respectively. In HIV-negative MSM, IRC produced even better results with clearance of 81% and recurrence rates of 53% after a mean of 238 days; 28% and 0% after first, second, and third ablations.34 The clearance results of our per lesion analysis were comparable to these clearance rates. Though IRC is safe and effective, it requires local anesthesia or sedation, may require several applications, and is more expensive than TCA. Moreover, use of TCA allows people with almost no additional training to treat AIN identifiable on HRA, whereas other modalities such as IRC and surgery require further training and expertise. However, regular follow-up after treatment with TCA is paramount to ensure regression/clearance of previously treated lesions and to address any recurrent or newly appearing lesions. Hence TCA treatment may require more patient visits compared with IRC.
One of the main limiting factors of our study was the small sample size. Normal cytology and visual absence of all lesions were considered the criteria for response, but random biopsying may have yielded results of AIN in some patients, leading us to overestimate the per lesion and per patient response rates. Conversely, we may also have overestimated recurrence after treatment because lesions detected during follow-up could have been newly appearing lesions and not necessarily the recurrence of the treated lesion. Other limitations of the study include the generalizability of the results because we selected patients with limited disease and treatment at more frequent intervals may have led to better efficacy. Finally, in some patients, we used cytology to classify the grade of disease before TCA therapy. Anal cytology is likelier to underestimate the grade of true disease rather than overestimate it. Therefore, it is possible that we underestimated the proportion of patients with AIN 2/3, but because this was a small proportion of our patients, the effect on our data is likely to be limited.
This is the first study that describes the efficacy and safety of TCA in the treatment of AIN. Given its ease of use, low cost, and good safety profile, TCA represents a reasonable first-line therapy with carefully selected patients. Larger, prospective randomized studies are needed to determine efficacy of TCA for treatment of AIN in comparison with other treatment modalities and ultimately to reduce the risk of progression of AIN to invasive cancer.
TCA may be a safe, inexpensive, and effective treatment in patients with 2 or fewer discrete AIN lesions, particularly for patients younger than 50 years of age. Follow-up is needed because of the high potential for lesion recurrence.
The authors would like to thank Barbara Grimes and Su-Chun Cheng for their valuable help in the data analysis.
1. Lacey CJ. Therapy for genital human papillomavirus-related disease. J Clin Virol. 2005;32(Suppl 1):S82-S90.
2. Hagensee ME, Cameron JE, Leigh JE, et al. Human papillomavirus infection and disease in HIV-infected individuals. Am J Med Sci. 2004;328:57-63.
3. Holly EA, Whittemore AS, Aston DA, et al. Anal cancer incidence: genital warts, anal fissure or fistula, hemorrhoids, and smoking. J Natl Cancer Inst. 1989;81:1726-1731.
4. Maggard MA, Beanes SR, Ko CY. Anal canal cancer: a population-based reappraisal. Dis Colon Rectum. 2003;46:1517-1523. Discussion 1523-1514. Author reply 1524.
5. Johnson LG, Madeleine MM, Newcomer LM, et al. Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000. Cancer. 2004;101:281-288.
6. Melbye M, Frisch M. The role of human papillomaviruses in anogenital cancers. Semin Cancer Biol. 1998;8:307-313.
7. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5-26.
8. Daling JR, Weiss NS, Hislop TG, et al. Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. N Engl J Med. 1987;317:973-977.
9. Uronis HE, Bendell JC. Anal cancer: an overview. Oncologist. 2007;12:524-534.
10. Durante AJ, Williams AB, Da Costa M, et al. Incidence of anal cytological abnormalities in a cohort of human immunodeficiency virus-infected women. Cancer Epidemiol Biomarkers Prev. 2003;12:638-642.
11. Williams AB, Darragh TM, Vranizan K, et al. Anal and cervical human papillomavirus infection and risk of anal and cervical epithelial abnormalities in human immunodeficiency virus-infected women. Obstet Gynecol. 1994;83:205-211.
12. Chin-Hong PV, Palefsky JM. Natural history and clinical management of anal human papillomavirus disease in men and women infected with human immunodeficiency virus. Clin Infect Dis. 2002;35:1127-1134.
13. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst. 2000;92:1500-1510.
14. Goedert JJ, Cote TR, Virgo P, et al. Spectrum of AIDS-associated malignant disorders. Lancet. 1998;351:1833-1839.
15. Abbasakoor F, Boulos PB. Anal intraepithelial neoplasia. Br J Surg. 2005;92:277-290.
16. Wienecke R, Brockmeyer NH, Kreuter A. [Human papilloma virus-induced disease in HIV-positive patients]. Hautarzt. 2006;57:994-998.
17. Horster S, Thoma-Greber E, Siebeck M, et al. Is anal carcinoma a HAART-related problem? Eur J Med Res. 2003;8:142-146.
18. Palefsky JM, Holly EA, Efirdc JT, et al. Anal intraepithelial neoplasia in the highly active antiretroviral therapy era among HIV-positive men who have sex with men. AIDS. 2005;19:1407-1414.
19. Piketty C, Darragh TM, Heard I, et al. High prevalence of anal squamous intraepithelial lesions in HIV-positive men despite the use of highly active antiretroviral therapy. Sex Transm Dis. 2004;31:96-99.
20. Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep. 2006;55:1-94.
21. Watson AJ, Smith BB, Whitehead MR, et al. Malignant progression of anal intra-epithelial neoplasia. ANZ J Surg. 2006;76:715-717.
22. Palefsky JM, Holly EA, Hogeboom CJ, et al. Virologic, immunologic, and clinical parameters in the incidence and progression of anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual men. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17:314-319.
23. Palefsky JM. Anal squamous intraepithelial lesions in human immunodeficiency virus-positive men and women. Semin Oncol. 2000;27:471-479.
24. Palefsky JM. Anal squamous intraepithelial lesions: relation to HIV and human papillomavirus infection. J Acquir Immune Defic Syndr. 1999;21 (Suppl 1):S42-S48.
25. Palefsky JM, Holly EA, Hogeboom CJ, et al. Anal cytology as a screening tool for anal squamous intraepithelial lesions. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;14:415-422.
© 2009 Lippincott Williams & Wilkins, Inc.